Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07088913 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT07088913 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 20 participants.
The verdict
NCT07088913, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the effect of capivasertib on the pharmacokinetics (PK) of oral rosuvastatin in healthy participants.
Interventions
- DRUG Capivasertib
- DRUG Rosuvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-07-28 |
| Est. Completion | 2026-02-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07088913
The ClinicalTrials.gov registry entry for NCT07088913 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Capivasertib is the first listed.
NCT07088913 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07088913 about?
NCT07088913 is a clinical study titled "A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants". The purpose of the study is to assess the effect of capivasertib on the pharmacokinetics (PK) of oral rosuvastatin in healthy participants.
What is the current status of trial NCT07088913?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-07-28. Estimated completion is 2026-02-20.
What interventions are being tested in trial NCT07088913?
The interventions under investigation include: Capivasertib (DRUG), Rosuvastatin (DRUG).
Who is sponsoring clinical trial NCT07088913?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.